There's a lot of excitement about the European clinical trials for BC 007, a drug that cured 4 people of long COVID. Some were disappointed there weren't American clinical trials.

There's a drug called RSLV-132 that works in a similar way to BC 007. While BC 007 neutralises specific autoantibodies, RSLV-132 neutralises a broader range of RNA-containing autoantibodies.

In a way, this can be an advantage. Yale found Long COVID is associated with a wide range of autoantibodies. These were not limited to the GPCR autoantibodies which BC 007 targets. So RSLV-132 might end up being more effective than BC 007. I'm a patient not a doctor/scientist, but it looks promising to me. Talk to your doctor before signing up.

RSLV-132 should also be safe. It has been tested in a phase 2 clinical trial of 20 patients with Sjogren's syndrome where it was found to have be safe and caused a significant decrease in fatigue.

The long COVID trial is still accepting registrations. Details are on this page.

To join, contact [email protected] or (208) 727 7010. Places are available in Seattle, WA; Pompano Beach, FL; and Knoxville, TN.

If you're excited about RSLV-132, write to the Secretary of Health and Human Services ([email protected]) and ask him to grant Emergency Use Authorization for it once the phase 2 clinical trial is complete.